Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Unusually-High Trading Volume – What’s Next?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw unusually-high trading volume on Thursday . Approximately 1,111 shares traded hands during mid-day trading, an increase of 66% from the previous session’s volume of 671 shares.The stock last traded at $15.05 and had previously closed at $14.71.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

The firm has a market cap of $7.52 billion, a PE ratio of 15.24 and a beta of 0.33. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $14.47 and its two-hundred day simple moving average is $14.82.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.